Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma : half of patients respond to a four-dose treatment program
収録刊行物
-
- J Clin Oncol
-
J Clin Oncol 16 2825-2833, 1998